

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 8992
)
Alan BARGE)
)
Application No.: 10/530.567) Group Art Unit: 1614
)
Filed: April 7, 2005) Examiner: Finn, Meghan R.
)
FOR: USE OF THE QUINAZOLINE)
DERIVATIVE ZD6474 COMBINED)
WITH GEMCITABINE AND)
OPTIONALLY IONISING RADIATION)
IN THE TREATMENT OF DISEASES)
ASSOCIATED WITH ANGIOGENESIS)
AND/OR INCREASED VASCULAR)
PERMEABILITY)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: June 4, 2008

Sir:

AMENDMENT AND RESPONSE

This is in response to the Action mailed December 4, 2007, the time for responding to which has been extended to and including June 4, 2008 by Petition and authorization for payment of fees submitted herewith. Please amend the claims as follows:

Amendment to the Specification begins on page 3 of this paper.

Amendments to the Claims begin on page 4 of this paper.

Remarks/Arguments begin on page 5 of this paper.

The Examiner's attention is also called to the two literature references attached to this Amendment and Response which are submitted in furtherance of the arguments presented below, specifically Conrad et al. "Antiangiogenic and antitumor activity of a novel vascular endothelial

growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model” *Anti-Cancer Drugs* 18(5):569-579 (2007); and Bianco et al. “Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer” *Clinical Cancer Research* 12(23):7099-7107 (2006).